Publication Library

Christoph T., 2018. Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model

Click here to request the full paper

Schiene K et al., 2018.Inhibition of experimental visceral pain in rodents by cebranopadol

Click here to request the full paper

Schiene, K., 2018. Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain

Click here to request the full paper

Tzschentke TM & Rutten K.. 2018. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.

Click here to request the full paper

Kleideiter E., 2018. Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic

Click here to request the full paper

Tzschentke TM., 2018. Limited potential of cebranopadol to produce opioid-type physical dependence in rodents

Click here to request the full paper

Tzschentke TM., 2017. Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain

Click here to request the full paper

Linz K et al., 2017. Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity

Click here to request the full paper

Dahan A., 2017. Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers

Click here to request the full paper

Christoph A et al., 2017. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial

Click here to request the full paper

Linz K et al., 2014. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist

Click here to request the full paper

Schunk S et al., 2014. Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol

Click here to request the full paper

Valdor M et al., 2018. RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors

Click here to request the full paper

Patel R et al., 2015. Electrophysiological characterization of activation state-dependent Ca(v)2 channel antagonist TROX-1 in spinal nerve injured rats

Click here to request the full paper

Nardi A et al. 2012. Advances in targeting voltage-gated sodium channels with small molecules

Click here to request the full paper

Steinhagen H & Damann N. 2012. Channeling drug discovery

Click here to request the full paper

Pan et al., 2018. Nociceptin/orphanin FQ opioid peptide-receptor expression in pachyonychia congenita

Click here to request the full paper

Rutten et al., 2018. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain

Click here to request the full paper

Anand P et al., 2016. Nociceptin/orphanin FQ receptor expression in clinical pain disorders and functional effects in cultured neurons

Click here to request the full paper

Schiene K et al., 2015. Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and µ-opioid receptor agonism

Click here to request the full paper

Rutten K et al., 2014. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia

Click here to request the full paper

Schunk S. et al., 2014. Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists

Click here to request the full paper

Schröder W et al., 2014. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists

Click here to request the full paper

Rutten K et al., 2010. Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats

Click here to request the full paper

Rutten K et al., 2010. Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats

Click here to request the full paper

Bloms-Funke P et al., 2000. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor

Click here to request the full paper

Christoph T et al., 2006. The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism

Click here to request the full paper

Christoph T et al., 2006. Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms.

Click here to request the full paper

Gaunitz C et al., 2002. Formalin-induced changes of NMDA receptor subunit expression in the spinal cord of the rat.

Click here to request the full paper

Tzschentke TM, 2002. Glutamatergic mechanisms in different disease states: overview and therapeutical implications -- an introduction.

Click here to request the full paper

Chizh BA, 2002. Novel approaches to targeting glutamate receptors for the treatment of chronic pain: review article.

Click here to request the full paper

Chizh BA et al., 2001. NMDA receptor antagonists as analgesics: focus on the NR2B subtype.

Click here to request the full paper

Chizh BA et al., 2001. Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil.

Click here to request the full paper

Tzschentke TM et al., 2000. Blockade of behavioral sensitization by MK-801: fact or artifact? A review of preclinical data.

Click here to request the full paper

Chizh BA et al., 2000. The N-methyl-D-aspartate antagonistic and opioid components of d-methadone antinociception in the rat spinal cord.

Click here to request the full paper

Pippel et al., 2017. Localization of the gate and selectivity filter of the full-length P2X7 receptor

Click here to request the full paper.

Hausmann R, Kless A, Schmalzing G. 2015. Key sites for P2X receptor function and multimerization: overview of mutagenesis studies on a structural basis

Click here to request the full paper

Hausmann R et al., 2014. A hydrophobic residue in position 15 of the rP2X3 receptor slows desensitization and reveals properties beneficial for pharmacological analysis and high-throughput screening

Click here to request the full paper

Saul A et al., 2013. Heteromeric assembly of P2X subunits

Click here to request the full paper

Hausmann R et al., 2013.Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptor

Click here to request the full paper

Wolf C et al., 2011. Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking

Click here to request the full paper

Gerevich Z et al., 2007. Metabotropic P2Y receptors inhibit P2X3 receptor-channels via G protein-dependent facilitation of their desensitization

Click here to request the full paper

Ramos-Zepeda G et al., 2004. Spinal vs. supraspinal antinociceptive activity of the adenosine A(1) receptor agonist cyclopentyl-adenosine in rats with inflammation

Click here to request the full paper

Gerevich Z et al., 2004. Inhibition of N-type voltage-activated calcium channels in rat dorsal root ganglion neurons by P2Y receptors is a possible mechanism of ADP-induced analgesia

Click here to request the full paper

Chizh BA, Illes P.. 2001. P2Y receptor-mediated inhibition of voltage-dependent Ca2+ channels in rat dorsal root ganglion neurons

Click here to request the full paper

Fischer W et al., 2003. Characterization of P2X3, P2Y1 and P2Y4 receptors in cultured HEK293-hP2X3 cells and their inhibition by ethanol and trichloroethanol

Click here to request the full paper

Borvendeg SJ et al., 2003. Subsensitivity of P2X but not vanilloid 1 receptors in dorsal root ganglia of rats caused by cyclophosphamide cystitis

Click here to request the full paper

Chizh BA, Illes P.. 2001. IP2X receptors and nociception

Click here to request the full paper

Stollenwerk A., 2018. Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic

Click here to request the full paper

Serrie A et al., 2017. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study

Click here to request the full paper

Lange B et al., 2017. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies

Click here to request the full paper

Baron R et al., 2017. Retrospective analyses versus RCTs: comparing like with like?

Click here to request the full paper

Kress HG et al., 2016. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain

Click here to request the full paper

Baron R et al., 2016. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study

Click here to request the full paper

Baron R et al., 2016. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study

Click here to request the full paper

Sánchez Del Águila MJ et al., 2015. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain

Click here to request the full paper

Sadeghi M et al., 2015. μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons

Click here to request the full paper

Hillewaert V et al., 2015. Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC-MS/MS

Click here to request the full paper

Elling C et al., 2015. Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy

Click here to request the full paper

Eichenbaum G et al., 2015. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency

Click here to request the full paper

Buynak R et al., 2015. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial

Click here to request the full paper

Baron R et al., 2015. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study

Click here to request the full paper

Baron R et al., 2015. Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study

Click here to request the full paper

Vinik et al., 2014. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy

Click here to request the full paper

Tzschentke TM et al., 2014. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol

Click here to request the full paper

Schikowski A et al., 2014. Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients

Click here to request the full paper

Sabatowski R et al., 2014. Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial

Click here to request the full paper

Meneghini V et al., 2014. The noradrenergic component in tapentadol action counteracts μ-opioid receptor-mediated adverse effects on adult neurogenesis

Click here to request the full paper

Kress HG et al., 2014. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain

Click here to request the full paper

Kögel B et al., 2014. Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs

Click here to request the full paper

Galia E., 2014. Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: results of in vitro laboratory analyses

Click here to request the full paper

Etropolski M et al., 2014. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials

Click here to request the full paper

Cowan A et al., 2014. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit

Click here to request the full paper

Caputi FF et al., 2014. Opioid receptor gene expression in human neuroblastoma SH-SY5Y cells following tapentadol exposure

Click here to request the full paper

Zannikos PN et al., 2013. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects

Click here to request the full paper

Steigerwald I et al., 2013. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain

Click here to request the full paper

Schwittay A et al., 2013. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists

Click here to request the full paper

Göhler K et al., 2013. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations

Click here to request the full paper

Gálvez R et al., 2013. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study

Click here to request the full paper

Etropolski M et al., 2013. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain

Click here to request the full paper

Christoph T et al., 2013. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice

Click here to request the full paper

Tzschentke TM et al., 2012. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis

Click here to request the full paper

Steigerwald I et al., 2012. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study

Click here to request the full paper

Steigerwald I et al., 2012. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study

Click here to request the full paper

Raffa RB et al., 2012. Mechanistic and functional differentiation of tapentadol and tramadol

Click here to request the full paper

Obradovic M et al., 2012. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs

Click here to request the full paper

Ikenberg R et al., 2012. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine

Click here to request the full paper

Vorsanger G et al., 2011. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients

Click here to request the full paper

Schwartz S et al., 2011. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial

Click here to request the full paper

Schröder W et al., 2011. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia

Click here to request the full paper

Schiene K, De Vry J, Tzschentke TM.. 2011. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain

Click here to request the full paper

Kögel B et al., 2011. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice

Click here to request the full paper

Christoph T et al., 2011. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain

Click here to request the full paper

Wild JE et al., 2010. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain

Click here to request the full paper

Terlinden R et al., 2010. In vitro and in vivo characterization of tapentadol metabolites

Click here to request the full paper

Schröder W et al., 2010. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain

Click here to request the full paper

Oh C et al., 2010. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects

Click here to request the full paper

Lange B et al., 2010. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain

Click here to request the full paper

Christoph T, De Vry J, Tzschentke TM.. 2010. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain

Click here to request the full paper

Afilalo M, Stegmann JU & Upmalis D. 2010 .Tapentadol immediate release: a new treatment option for acute pain management

Click here to request the full paper

Tzschentke TM et al., 2009. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule

Click here to request the full paper

Hartrick C et al., 2009. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study

Click here to request the full paper

Hale M et al., 2009.Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study

Click here to request the full paper

Daniels SE et al., 2009. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain

Click here to request the full paper

Daniels S et al., 2009. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain

Click here to request the full paper

Stegmann JU et al., 2008. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery

Click here to request the full paper

Kneip C et al, 2008. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes

Click here to request the full paper

Kleinert R et al., 2008. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study

Click here to request the full paper

Tzschentke TM et al., 2007. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties

Click here to request the full paper

Terlinden R et al., 2007. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects

Click here to request the full paper

Christoph T et al., 2018. Investigation of TRPV1 loss-of-function phenotypes in TRPV1 Leu206Stop mice generated by N-ethyl-N-nitrosourea mutagenesis

Click here to request the full paper

Lee S et al., 2017. Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

Click here to request the full paper

Lee S et al., 2017. t-Butyl pyridine and phenyl C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

Click here to request the full paper

Ryu H et al., 2015. Pyridine C-region analogs of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

Click here to request the full paper.

Tran PT et al., 2015. α-Substituted 2-(3-fluoro-4-methylsulfonamidophenyl)acetamides as potent TRPV1 antagonists

Click here to request the full paper

Sun W et al., 2015. 6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists

Click here to request the full paper

Ann J et al., 2015. Structure activity relationships of benzyl C-region analogs of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides as potent TRPV1 antagonists

Click here to request the full paper

Ryu H et al., 2014. 2-Alkyl/alkenyl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists

Click here to request the full paper

Ryu H et al., 2014. 2-Alkyl/alkenyl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists

Click here to request the full paper

Kim MS et al., 2012. 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region

Click here to request the full paper

Christoph T et al., 2008. Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice

Click here for access to the full paper

Christoph et al., 2007. Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1

Click here to request the full paper

Christoph T et al., 2006. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo

Click here to request the full paper

Vulcu SD et al., 2004. Proton conductance of human transient receptor potential-vanilloid type-1 expressed in oocytes of Xenopus laevis and in Chinese hamster ovary cells

Click here to request the full paper

Goswami C et al., 2004. Identification and characterization of a Ca2+ -sensitive interaction of the vanilloid receptor TRPV1 with tubulin

Click here to request the full paper

Behrendt HJ et al., 2004. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay

Click here to request the full paper

Vulcu SD et al., 2003. The cAMP pathway sensitizes VR1 expressed in oocytes from Xenopus laevis and in CHO cells

Click here to request the full paper

Borvendeg SJ et al., 2003. Subsensitivity of P2X but not vanilloid 1 receptors in dorsal root ganglia of rats caused by cyclophosphamide cystitis

Click here to request the full paper

Jahnel R et al., 2003. Dual expression of mouse and rat VRL-1 in the dorsal root ganglion derived cell line F-11 and biochemical analysis of VRL-1 after heterologous expression

Click here to request the full paper

Himmel HM et al., 2002. The arginine-rich hexapeptide R4W2 is a stereoselective antagonist at the vanilloid receptor 1: a Ca2+ imaging study in adult rat dorsal root ganglion neurons

Click here to request the full paper

Jahnel R et al., 2001. Biochemical characterization of the vanilloid receptor 1 expressed in a dorsal root ganglia derived cell line

Click here to request the full paper

Rutten K et al., 2018. Standard analgesics reverse burrowing deficits in a rat CCI model of neuropathic pain, but not in models of type 1 and type 2 diabetes-induced neuropathic pain

Click here to request the full paper

Treister R et al., 2018. Accurate pain reporting training diminishes the placebo response: Results from a randomised, double-blind, crossover trial

Click here to request the full paper

Wodarski R et al., 2016. Cross-centre replication of suppressed burrowing behaviour as an ethologically relevant pain outcome measure in the rat: a prospective multicentre study

Click here to request the full paper

Alansary D et al., 2016. Thiol dependent intramolecular locking of Orai1 channels

Click here to request the full paper

Schröder W, Alique M, & Herrero JF, 2016. Effects of the mas-related gene (Mrg) C receptor agonist BAM6-22 on nociceptive reflex activity in naive, monoarthritic and mononeuropathic rats after intraplantar and intrathecal administration

Click here to request the full paper

Quetglas EG et al., 2015. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease

Click here to request the full paper

Bourgeois C et al., 2014. Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ-opioid receptor agonists

Click here to request the full paper

Rutten K et al., 2014. Pharmacological validation of a refined burrowing paradigm for prediction of analgesic efficacy in a rat model of sub-chronic knee joint inflammation

Click here to request the full paper

Rutten K et al., 2014. Burrowing as a non-reflex behavioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation

Click here to request the full paper

Beier H et al., 2008. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism: the interaction between tramadol and its active metabolite on micro-opioid agonism and monoamine reuptake inhibition, in the rat

Click here to request the full paper

Christoph T et al., 2007. Tramadol has a better potency ratio relative to morphine in neuropathic than in nociceptive pain models

Click here to request the full paper

Eitrich T et al., 2007. Classification of highly unbalanced CYP450 data of drugs using cost sensitive machine learning techniques

Click here to request the full paper

Kögel B et al., 2005. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice

Click here to request the full paper

Christoph T et al., 2005. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain

Click here to request the full paper

Streng T et al., 2003. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats

Click here to request the full paper

Pandita RK et al., 2003. Actions of tramadol on micturition in awake, freely moving rats

Click here to request the full paper

Gillen & Maul, 2002. New pharmacological strategies for pain relief

Click here to request the full paper